Quality of end-of-life care with non-malignant liver disease: Analysis of the VOICES National Survey of Bereaved People.
cirrhosis
palliative care
quality of life
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
25
08
2022
received:
24
02
2022
accepted:
12
09
2022
pubmed:
18
9
2022
medline:
25
1
2023
entrez:
17
9
2022
Statut:
ppublish
Résumé
Patients with liver disease struggle to access palliative care. We aimed to compare carers' perceptions of end-of-life care for decedents with non-malignant liver disease, malignant liver disease and other non-malignant diseases, and to identify associated factors in non-malignant liver disease. A retrospective analysis of individual-level data from the National Survey of Bereaved People 2011-2015. More decedents with non-malignant liver disease died in hospital than other diseases (76.9% vs. 40.9% vs. 50.2%, p < .001), despite 89% wishing to die at home. Fewer decedents received home/hospice specialist palliative care compared with those with malignant liver disease (10.0% vs. 54.6%, p < .001). Carers of decedents with non-malignant liver disease were less likely to rate overall end-of-life care quality as outstanding/excellent (29.3% vs. 43.9% vs. 42.3%, p < .001). For this group, poorer care was associated with younger (65-74 vs. 18-64 years, OR [odds ratio] 1.39, p = .01), more socially deprived decedents (OR .78, p = .02), and better care with greater social support (OR 1.82, p < .001) and community specialist palliative care involvement (OR 1.80, p < .001). There was no association between outstanding/excellent rating and underlying cause of non-malignant liver disease (alcohol-related vs. non-alcohol-related, p = .92) or place of death (hospital vs. non-hospital, p = .476). End-of-life care could be improved by integrating hepatology and community services, particularly specialist palliative care, and advance care planning to facilitate care and death (where desired) at home. However, death in hospital may be appropriate for those with non-malignant liver disease.
Sections du résumé
BACKGROUND AND AIMS
Patients with liver disease struggle to access palliative care. We aimed to compare carers' perceptions of end-of-life care for decedents with non-malignant liver disease, malignant liver disease and other non-malignant diseases, and to identify associated factors in non-malignant liver disease.
METHODS
A retrospective analysis of individual-level data from the National Survey of Bereaved People 2011-2015.
RESULTS
More decedents with non-malignant liver disease died in hospital than other diseases (76.9% vs. 40.9% vs. 50.2%, p < .001), despite 89% wishing to die at home. Fewer decedents received home/hospice specialist palliative care compared with those with malignant liver disease (10.0% vs. 54.6%, p < .001). Carers of decedents with non-malignant liver disease were less likely to rate overall end-of-life care quality as outstanding/excellent (29.3% vs. 43.9% vs. 42.3%, p < .001). For this group, poorer care was associated with younger (65-74 vs. 18-64 years, OR [odds ratio] 1.39, p = .01), more socially deprived decedents (OR .78, p = .02), and better care with greater social support (OR 1.82, p < .001) and community specialist palliative care involvement (OR 1.80, p < .001). There was no association between outstanding/excellent rating and underlying cause of non-malignant liver disease (alcohol-related vs. non-alcohol-related, p = .92) or place of death (hospital vs. non-hospital, p = .476).
CONCLUSIONS
End-of-life care could be improved by integrating hepatology and community services, particularly specialist palliative care, and advance care planning to facilitate care and death (where desired) at home. However, death in hospital may be appropriate for those with non-malignant liver disease.
Identifiants
pubmed: 36114763
doi: 10.1111/liv.15428
pmc: PMC10087137
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
308-316Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Pain Symptom Manage. 2020 Mar;59(3):590-598
pubmed: 31655192
J Hepatol. 2018 Dec;69(6):1260-1273
pubmed: 30243996
Hepatology. 2018 Sep;68(3):872-882
pubmed: 29579356
JAMA Netw Open. 2021 Mar 1;4(3):e210677
pubmed: 33662135
Palliat Med. 2004 Sep;18(6):525-42
pubmed: 15453624
J Am Med Dir Assoc. 2014 Jul;15(7):477-489
pubmed: 24598477
Liver Int. 2023 Feb;43(2):308-316
pubmed: 36114763
Palliat Med. 2014 Oct;28(9):1081-98
pubmed: 24821710
Ann Palliat Med. 2016 Apr;5(2):76-82
pubmed: 27121735
Palliat Med. 2018 May;32(5):908-918
pubmed: 29393806
Dig Dis Sci. 2015 Sep;60(9):2628-35
pubmed: 25732712
Medicine (Baltimore). 2016 Nov;95(46):e5394
pubmed: 27861375
Psychosomatics. 2020 May - Jun;61(3):238-253
pubmed: 32033835
PLoS One. 2015 Sep 10;10(9):e0137251
pubmed: 26356477
BMC Palliat Care. 2017 Dec 08;16(1):68
pubmed: 29216873
BMJ Open. 2015 Apr 08;5(4):e007451
pubmed: 25854973
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1612-1619.e4
pubmed: 28179192
Palliat Med. 2019 Jan;33(1):24-36
pubmed: 30345878
Palliat Med. 2018 May;32(5):919-929
pubmed: 29516776
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):95-103
pubmed: 29150405
JAMA. 2016 Nov 22;316(20):2104-2114
pubmed: 27893131
BMJ Open. 2015 Nov 19;5(11):e009241
pubmed: 26586325
Palliat Med. 2018 Sep;32(8):1322-1333
pubmed: 29874525
Dig Dis Sci. 2021 May;66(5):1446-1451
pubmed: 32500286
BMJ Support Palliat Care. 2015 Dec;5(5):471-80
pubmed: 24644180
J Pain Symptom Manage. 2015 Dec;50(6):882-6.e2
pubmed: 26303186
Lancet. 2018 Dec 1;392(10162):2398-2412
pubmed: 30473364
JAMA. 2020 Oct 13;324(14):1439-1450
pubmed: 33048152
Lancet Gastroenterol Hepatol. 2019 Jan;4(1):52-62
pubmed: 30472051
BMJ Support Palliat Care. 2019 Feb 13;:
pubmed: 30760459
Cochrane Database Syst Rev. 2020 Feb 27;2:CD013022
pubmed: 32104908
Lancet. 2013 Nov 9;382(9904):1537-8
pubmed: 24209811
J Pain Symptom Manage. 2016 Sep;52(3):412-419.e1
pubmed: 27265812
J Pain Symptom Manage. 2019 Nov;58(5):766-773
pubmed: 31326503
J Palliat Med. 2020 Jan;23(1):97-106
pubmed: 31397615
Palliat Med. 2014 Sep;28(8):1000-25
pubmed: 24651708
JAMA Intern Med. 2021 May 1;181(5):652-660
pubmed: 33720273
Clin Gastroenterol Hepatol. 2018 Jan;16(1):142-143
pubmed: 28711690
Cochrane Database Syst Rev. 2013 Jun 06;(6):CD007760
pubmed: 23744578
J Palliat Med. 2019 Nov;22(11):1445-1448
pubmed: 30964375
J Crit Care. 2018 Dec;48:290-295
pubmed: 30269008
BMJ. 2005 Apr 30;330(7498):1007-11
pubmed: 15860828
Clin Gastroenterol Hepatol. 2014 Apr;12(4):692-8
pubmed: 23978345
Hepatology. 2017 Nov;66(5):1585-1591
pubmed: 28660622
MDM Policy Pract. 2019 Sep 10;4(2):2381468319866451
pubmed: 31535032
BMJ. 2017 Jul 4;357:j2925
pubmed: 28676557
BMC Med. 2019 Mar 22;17(1):50
pubmed: 30898162
Frontline Gastroenterol. 2016 Jan;7(1):4-9
pubmed: 28839829